Connection

THOMAS COOPER to Myotonic Dystrophy

This is a "connection" page, showing publications THOMAS COOPER has written about Myotonic Dystrophy.
Connection Strength

12.294
  1. MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model. J Clin Invest. 2025 Feb 11; 135(7).
    View in: PubMed
    Score: 0.852
  2. Rescue of Scn5a mis-splicing does not improve the structural and functional heart defects of a DM1 heart mouse model. Hum Mol Genet. 2024 10 07; 33(20):1789-1799.
    View in: PubMed
    Score: 0.832
  3. The role of Limch1 alternative splicing in skeletal muscle function. Life Sci Alliance. 2023 06; 6(6).
    View in: PubMed
    Score: 0.748
  4. Alternative splicing mediates the compensatory upregulation of MBNL2 upon MBNL1 loss-of-function. Nucleic Acids Res. 2023 02 22; 51(3):1245-1259.
    View in: PubMed
    Score: 0.744
  5. Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2. Int J Mol Sci. 2022 Nov 26; 23(23).
    View in: PubMed
    Score: 0.731
  6. Increased nuclear but not cytoplasmic activities of CELF1 protein leads to muscle wasting. Hum Mol Genet. 2020 06 27; 29(10):1729-1744.
    View in: PubMed
    Score: 0.619
  7. Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1. Muscle Nerve. 2019 12; 60(6):779-789.
    View in: PubMed
    Score: 0.590
  8. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet. 2018 08 15; 27(16):2789-2804.
    View in: PubMed
    Score: 0.543
  9. Roles for RNA-binding proteins in development and disease. Brain Res. 2016 09 15; 1647:1-8.
    View in: PubMed
    Score: 0.459
  10. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep. 2014 Jan 30; 6(2):336-45.
    View in: PubMed
    Score: 0.395
  11. Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13570-5.
    View in: PubMed
    Score: 0.383
  12. Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther. 2013 May; 24(5):499-507.
    View in: PubMed
    Score: 0.370
  13. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A. 2012 Mar 13; 109(11):4221-6.
    View in: PubMed
    Score: 0.347
  14. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010 Sep 15; 19(18):3614-22.
    View in: PubMed
    Score: 0.310
  15. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010 Mar 15; 19(6):1066-75.
    View in: PubMed
    Score: 0.299
  16. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009 Dec; 37(Pt 6):1281-6.
    View in: PubMed
    Score: 0.297
  17. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009 Dec; 119(12):3797-806.
    View in: PubMed
    Score: 0.296
  18. Chemical reversal of the RNA gain of function in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009 Nov 03; 106(44):18433-4.
    View in: PubMed
    Score: 0.295
  19. Molecular biology. Neutralizing toxic RNA. Science. 2009 Jul 17; 325(5938):272-3.
    View in: PubMed
    Score: 0.290
  20. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2008 Feb 19; 105(7):2646-51.
    View in: PubMed
    Score: 0.262
  21. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007 Oct 12; 28(1):68-78.
    View in: PubMed
    Score: 0.256
  22. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest. 2007 Oct; 117(10):2802-11.
    View in: PubMed
    Score: 0.256
  23. Alternative splicing in disease. Adv Exp Med Biol. 2007; 623:212-23.
    View in: PubMed
    Score: 0.243
  24. A reversal of misfortune for myotonic dystrophy? N Engl J Med. 2006 Oct 26; 355(17):1825-7.
    View in: PubMed
    Score: 0.240
  25. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol. 2006; 44:133-59.
    View in: PubMed
    Score: 0.227
  26. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci. 2005 Jul 01; 118(Pt 13):2923-33.
    View in: PubMed
    Score: 0.218
  27. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet. 2005 Jun 01; 14(11):1539-47.
    View in: PubMed
    Score: 0.216
  28. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 2002 Jul; 10(1):45-53.
    View in: PubMed
    Score: 0.178
  29. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001 Sep; 29(1):40-7.
    View in: PubMed
    Score: 0.168
  30. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998 May 01; 280(5364):737-41.
    View in: PubMed
    Score: 0.133
  31. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res. 2012 Jun 26; 1462:100-11.
    View in: PubMed
    Score: 0.087
  32. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol. 2011 Apr; 69(4):681-90.
    View in: PubMed
    Score: 0.081
  33. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats. Exp Neurol. 2008 Apr; 210(2):467-78.
    View in: PubMed
    Score: 0.065
  34. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006 Jul 01; 15(13):2138-45.
    View in: PubMed
    Score: 0.058
  35. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet. 2004 Jun; 74(6):1309-13.
    View in: PubMed
    Score: 0.050
  36. Pre-mRNA splicing and human disease. Genes Dev. 2003 Feb 15; 17(4):419-37.
    View in: PubMed
    Score: 0.046
  37. Myotonic dystrophy: discussion of molecular basis. Adv Exp Med Biol. 2002; 516:27-45.
    View in: PubMed
    Score: 0.043
  38. RNA processing and human disease. Cell Mol Life Sci. 2000 Feb; 57(2):235-49.
    View in: PubMed
    Score: 0.038
  39. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015 Jun; 25(6):858-71.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.